Navigation Links
Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
Date:9/15/2009

ok forward to working together to develop Anticalins as important medicines for the treatment of a number of ocular diseases. This collaboration further validates the potential for Anticalins as a new drug-class", said Claus Schalper, Interim-CEO of Pieris.

About Pieris AG

Pieris AG is an emerging biopharmaceutical company based in Freising, Germany focused on the discovery and advancement of Anticalins for the treatment of a variety of serious human diseases. The lead program PRS-050 is currently in late stage preclinical development for the indication oncology and will enter the clinic early next year. Founded in 2001, Pieris is funded by a number of international leading venture capital firms. For additional information, please visit the company's website, http://www.pieris-ag.com

For further information, please contact:

Dr. Birgit Zech, Director Business Development, Pieris AG, Phone: +49-8161-1411400


'/>"/>
SOURCE Pieris AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
2. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
3. Dr M Group Selects Health Robotics Technology Over RIVA for all of its I.V. Compounding Centers in South East Asia
4. Vita-Tech International, Inc. Donates One Ton of Vitamins To Polio Treatment Centers in Guinea, West Africa
5. SynCo Bio Partners Enters the Japanese Market as it Signs its First Agreement With a Japanese Pharmaceutical Company
6. New Jersey Surgery Centers Pick Health Informatics Consulting to Implement Patient Electronic Health Record Systems
7. DOE awards $377 million in funding for 46 energy frontier research centers
8. Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing
9. Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
10. Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders
11. NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... The Thomas Brain Health Center ... groundbreaking pilot study to see if early Alzheimer’s ... little as three to six months. , The ... medicine—will aggressively target and simultaneously treat the numerous ... brain. These include oxidative stress, neuroinflammation, mitochondrial dysfunction, ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... 23, 2015 ReliantHeart's HeartAssist5® Ventricular Assist ... flow through the device) in real time, and this ... world’s leading provider of Machine to Machine (M2M) communications ... Flow via VADLink.com can be monitored by ... drop in flow below a minimum threshold, the patient ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Data Presented Today at American Society of Clinical Oncology ... Therapeutics, Inc. today presented data demonstrating the use of ... cetuximab (ERBITUX(R)) on the colorectal cancer cells of individual ... the 54 primary colorectal cultures tested, eight percent were ...
... of response up to week 26 in moderate to ... infliximab. , , CHICAGO, June 1 New ... the Digestive Disease Week meeting demonstrate that Cimzia(R) (certolizumab ... week 26 for adult patients suffering from moderate to ...
... SOUTH PLAINFIELD, N.J., June 1 PTC Therapeutics, Inc. ... as Vice President of Commercial Operations. In this ... President, Commercial, and will be responsible for PTC,s patient ... reimbursement. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 2Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 4Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 5Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 6Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 7Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 8Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 9Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 10PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... School of Medicine of the University of Southern California ... female sex hormone, activates genes in breast-cancer cells. Greater ... lead to new treatments for the disease. ... Keck School,s Department of Biochemistry and Molecular Biology, was ...
... The TWAS 22nd General Meeting will take place on ... Theoretical Physics (ICTP), home to the Academy,s secretariat. TWAS,s ... by Romain Murenzi, executive director of TWAS; Fernando Quevedo, ... Affairs, Italy; and Jacob Palis, TWAS President, will highlight ...
... PARIS, Nov. 15, 2011 DigitalPersona, ... and endpoint protection solutions, today announced the availability ... biometric device manufacturers and solution providers. FingerJet OEM ... along with fast one-to-many identification and one-to-one verification. ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2TWAS 22nd General Meeting in Trieste 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 3
...
Ezrin/Radixin/Moesin Antibody...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Biology Products: